Drug Development

Cosmederm Bioscience is an early stage drug development company with a passion for discovery, design and development of new small molecules. Our new molecule demonstrates utility in targeting aberrant inflammation and immune-responses in autoimmune diseases with diminished pain and irritation as potential secondary benefits.

Technology

Cosmederm has developed a new small molecule (CB400) that has demonstrated powerful anti-inflammatory activity in in-vitro studies. CB400 is antiproliferative to both B Cells and T Cells. In Vitro studies with CB400 also showed a robust decrease in immune and inflammatory-related markers and cytokines such as sIgG, sIL-17A, sIL-17F, sIL-2 and sIL-6 was observed in the BT system, which models T cell dependent B cell activation. Decrease in immune markers such as sIgG and sIL-17A suggests a utility in targeting aberrant inflammation and immune-responses in autoimmune diseases.

Furthermore through in-vitro studies as well as a correlative analysis it has been determined that CB400 has a strong correlation (r ≥ 0.7) with BCR/Abl inhibitors approved for the treatment of multiple types of cancer, including CML and GIST.

 

Our Product Pipeline

The following compound is being developed as a prescription drug

Drug
Candidate
CB400
Clinical
Indication
Inflammatory/Autoimmune
Pre-Clinical
Phase I
Phase II
Phase III